Stada Arzneimittel AG Monday said it has begun talks with Cinven Partners LLP and Advent International Corporation, two separate bidders interested in acquiring up to 100% of the German pharmaceutical company.
The company said it received expressions of interest from both Cinven and Advent International and has initiated talks to allow them to discuss strategies and a potential offer price.
Stada said late Sunday it was weighing an approach from Cinven that valued its stock at 3.5 billion euros ($3.7 billion), as well as an approach from a second potential bidder that it didn’t name at the time. The Cinven offer had an indicative price of EUR56 per share, Stada said.
Shares surged 14% higher at the start of trading Monday on the news.
“Both legally non-binding expressions of interest (from the companies), which the Executive Board considered for some time, could offer in different ways attractive opportunities in the interest of the company,” Stada said.
Stada, which makes the cold treatment Grippostad, has been long been considered a possible takeover target for bigger rivals and private-equity firms. It had revenue of EUR2.12 billion in 2015.
By Sarah Sloat
Source: MarketWatch
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
